Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9NQW6
UPID:
ANLN_HUMAN
Alternative names:
-
Alternative UPACC:
Q9NQW6; Q5CZ78; Q6NSK5; Q9H8Y4; Q9NVN9; Q9NVP0
Background:
Anillin plays a pivotal role in cell division, ensuring the structural integrity of the cleavage furrow during cytokinesis. Its involvement in bleb assembly and podocyte cell migration underscores its significance in cellular dynamics and morphology.
Therapeutic significance:
Given its crucial role in podocyte function, Anillin's dysfunction is linked to Focal segmental glomerulosclerosis 8, a renal disease leading to severe morbidity. Targeting Anillin could offer novel therapeutic avenues for managing this condition.